The overall purpose of Core A is to provide a central structure to support the conduct of each of the three highly interrelated projects comprising this program project grant and also to Cores B and C. Core A supports administrative, regulatory, data management and statistical functions for all three projects as well as facilitating interactions with internal and external consultants to assure optimal scientific progress.
Specific Aims of Core A To provide administrative services and infrastructure (meeting scheduling, preparation of progress reports and manuscripts, budgeting, subcontract management, patient care budget development and monitoring, etc.) for Projects 1, 2, and 3 and Cores B and C. To provide regulatory services (protocol and IND preparation, IRB interactions, etc.) for Projects 1, 2 and 3 and Cores B and C. To provide centralized data management support for all protocols in Projects 1, 2, and 3. To provide biostatistical support for all protocols in Projects 1, 2, and 3. To provide internal and external advisory board consultation to assess the progress and direction of Projects 1, 2, and 3 and Cores B and C. To coordinate centralized Flow Cytometry and Molecular Diagnostic Testing for Biomarkers for Projects 1, 2, and 3. Core A provides equal levels of support to Projects 1, 2, and 3 (and also supplies administrative support to Cores B and C).

Public Health Relevance

The overall objective of this Program Project Grant is to improve the outcome of patients with hematologic malignancies by developing curative strategies using radiolabeled monoclonal antibodies in the setting of hematopoietic cell transplantation. This global Specific Aim will be pursued in three interactive, complementary projects that require a smoothly functioning administrative infrastructure.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA044991-25
Application #
8546160
Study Section
Special Emphasis Panel (ZCA1-RPRB-J)
Project Start
Project End
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
25
Fiscal Year
2013
Total Cost
$425,610
Indirect Cost
$117,324
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Cowan, Andrew J; Stevenson, Philip A; Cassaday, Ryan D et al. (2016) Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission. Biol Blood Marrow Transplant 22:380-5
Orozco, Johnnie J; Kenoyer, Aimee; Balkin, Ethan R et al. (2016) Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment. Blood 127:352-9
Rufener, Gregory A; Press, Oliver W; Olsen, Philip et al. (2016) Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab. Cancer Immunol Res 4:509-19
Chen, Robert; Gopal, Ajay K; Smith, Scott E et al. (2016) Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood 128:1562-6
Graf, Solomon A; Gopal, Ajay K (2016) Idelalisib for the treatment of non-Hodgkin lymphoma. Expert Opin Pharmacother 17:265-74
Green, D J; Bensinger, W I; Holmberg, L A et al. (2016) Bendamustine, etoposide and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in patients with multiple myeloma. Bone Marrow Transplant 51:1330-1336
Cassaday, Ryan D; Stevenson, Philip A; Gooley, Theodore A et al. (2015) High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma. Br J Haematol 171:788-97
Cassaday, Ryan D; Storer, Barry E; Sorror, Mohamed L et al. (2015) Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation. Biol Blood Marrow Transplant 21:281-7
Graf, S A; Stevenson, P A; Holmberg, L A et al. (2015) Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma. Ann Oncol 26:2323-8
Frost, Sofia H L; Miller, Brian W; Bäck, Tom A et al. (2015) α-Imaging Confirmed Efficient Targeting of CD45-Positive Cells After 211At-Radioimmunotherapy for Hematopoietic Cell Transplantation. J Nucl Med 56:1766-73

Showing the most recent 10 out of 121 publications